



# Immunization Program Provider Update October 13, 2022

**Merideth Plumpton, RN** - *Nurse Program Coordinator*

**Meghan Knowles** - *Communication and Training Coordinator*

# Agenda – 10/13/2022

Slides and recording will be posted by **end of the day** at [www.healthvermont.gov/COVID19-vaccine-healthpros#resources](http://www.healthvermont.gov/COVID19-vaccine-healthpros#resources)

- **Bivalent Boosters**
  - Pfizer (12+) and Moderna (18+)
  - Pfizer bivalent (5-11)
    - Ordering and Distribution
    - Storage and Administration
  - Availability of Moderna Bivalent Vaccine (6+)
    - Ordering – Opens 10/17
    - Storage and Administration
  - Communicating Bivalent Boosters
- **Vermont Vaccine Program Updates**
  - AAPVT Grant Funding available
  - Required COVID-19 Training Coming Soon
  - Upcoming VIMS notifications
  - Polio Vaccine
- **hMPXV (human monkeypox virus) – brief update**
  - JYNNEOS vaccine availability

## Contact Information

- Ordering, vaccine storage and handling, vaccine-specific information:  
[AHS.VDHImmunizationProgram@vermont.gov](mailto:AHS.VDHImmunizationProgram@vermont.gov)
- Immunization registry and reporting questions:  
[IMR@vermont.gov](mailto:IMR@vermont.gov)
- Program updates and e-mailed communications available on the Vaccine Information for Health Care Professionals Page:

Updates: [www.healthvermont.gov/disease-control/immunization-providers#vvpupdate](http://www.healthvermont.gov/disease-control/immunization-providers#vvpupdate)

E-mails: [www.healthvermont.gov/disease-control/immunization-providers#vvpmemo](http://www.healthvermont.gov/disease-control/immunization-providers#vvpmemo)

# Bivalent Boosters


# Pfizer-BioNTech (12+) and Moderna (18+) Bivalent Boosters

Administration as of 10/12/2022

# of people receiving bivalent booster

73.3K


Bivalent booster by reporting provider type



County	%
Addison	16%
Bennington	7%
Caledonia	9%
Chittenden	15%
Essex	4%
Franklin	8%
Grand Isle	14%
Lamoille	11%
Orange	10%
Orleans	7%
Rutland	9%
Washington	16%
Windham	12%
Windsor	10%
<b>VT</b>	<b>12%</b>

Bivalent booster by age and reported place of residence

● Non-VT ● VT



Data sources: Vermont Immunization Registry (10/12/2022); Vermont Department of Health Population estimates (2019)

# Pediatric Bivalent Booster Recommendation

- New Pfizer bivalent vaccine authorized as a booster dose in individuals 5 through 11 years of age (orange top) and current Moderna bivalent vaccine authorized as a booster dose in individuals 6 through 11 years of age (0.25 mL), and 12+ (0.5 mL).
- **EUAs no longer allow the monovalent vaccines to be used for booster doses.**
- CDC recommends that everyone who is eligible—including those who are moderately or severely immunocompromised—receive 1 dose of the updated (bivalent) booster if it has been at least 2 months since their last dose of a COVID-19 vaccine (either the final primary series dose or a monovalent booster)
- Vaccine recipients can mix brands from the primary series. For example, a 9-year-old who completed the Moderna primary series can receive a Pfizer-BioNTech updated booster.

# Primary Series vs. Booster

## Primary series vaccination

For primary series vaccination, three monovalent COVID-19 vaccines are recommended: Moderna, Novavax, and Pfizer-BioNTech. Bivalent mRNA vaccines are not authorized or approved at this time for primary series doses. The same vaccine product should be used for all doses of the primary series (see [Interchangeability of COVID-19 vaccine products](#)).

## Booster vaccination

For booster vaccination, an mRNA vaccine (i.e., Moderna or Pfizer-BioNTech) is recommended. Recommendations vary based on age and primary series product. **People ages 5 years and older are recommended to receive 1 age-appropriate bivalent mRNA booster dose after completion of any FDA-approved or FDA-authorized monovalent primary series or previously received monovalent booster dose(s). This new booster recommendation replaces all prior booster recommendations for this age group.** Monovalent mRNA vaccines are no longer authorized as a booster dose for people ages 5 years and older.

# Up-To-Date

CDC recommends everyone [stay up to date](#) with COVID-19 vaccination. You are considered up to date if you have completed a primary series and received the most recent booster dose recommended for you by CDC. CDC recommends that people:

- Ages 6 months through 4 years receive all COVID-19 original (monovalent) primary series doses.
- Ages 5 years and older receive all COVID-19 original (monovalent) primary series doses, plus an updated (bivalent) booster.

# Pediatric Bivalent Boosters EUAs

## Updated Moderna EUAs

- [Moderna COVID-19 Vaccines | FDA](#)
- [October 12, Dear Healthcare Provider Letter](#)
- [EUA Fact Sheet for Healthcare Providers \(6+ bivalent booster\)](#)
- [EUA Fact Sheet for Recipients \(6+ bivalent booster\)](#)

## Updated Pfizer EUAs

- [Pfizer-BioNTech COVID-19 Vaccines | FDA](#)
- [October 12, Dear Healthcare Provider Letter](#)
- [EUA Fact Sheet for Healthcare Providers \(5-11 primary series\)](#)
- [EUA Fact Sheet for Healthcare Providers \(5-11 bivalent booster\)](#)
- [EUA Fact Sheet for Healthcare Providers \(12+ bivalent booster\)](#)
- [EUA Fact Sheet for Recipients \(5-11 primary and booster\)](#)



# Pediatric Bivalent Boosters: 10/12 updates


<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

## Summary of recent changes (last updated October 12, 2022):


- New COVID-19 booster recommendations for people ages 5 years and older to receive 1 bivalent mRNA booster after completion of a monovalent primary series or previously received monovalent booster dose(s); these recommendations replace all prior booster recommendations for this age group
  - Recommendations for use of a bivalent Moderna booster dose in people ages 6–17 years
  - Recommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 5–11 years

# COVID-19 Vaccination Schedule Infographic for People who are NOT Moderately or Severely Immunocompromised


## People ages 6 months through 4 years



## People ages 5 through 11 years



## People ages 12 years and older




<https://www.cdc.gov/vaccines/covid-19/images/COVID19-vaccination-schedule-most-people.png>

# COVID-19 Vaccination Schedule Infographic for People who are Moderately or Severely Immunocompromised

## People ages 6 months through 4 years




## People ages 5 through 11 years



<https://www.cdc.gov/vaccines/covid-19/images/COVID19-vaccination-schedule-immunocompromised.png>

## People ages 12 years and older



# **Pediatric Bivalent Pfizer (5-11)**

# Pfizer 5-11 Bivalent Booster in Vermont


- Pfizer 5-11 bivalent booster vaccine was pre-ordered by 20 pediatric and family medicine practices.
- Approximately 21,000 newly eligible children 5-11.
- Pfizer and Moderna products will also be available at most [walk-in clinics](#).
- Major pharmacies have also received an allocation, call location for details.
- **Pfizer 5-11 bivalent will be back in VIMS for ordering on 10/24. Order as needed moving forward, planning for what you can use for 2-3 weeks until demand levels off.**

## Ancillary Kit Reminders

- You can not opt-out for pediatric Pfizer products, required diluent is a part of the ancillary delivery.
- If ancillary kits arrive, you can not refuse them, though materials can be used for other clinic needs.

# Pfizer 5-11 Bivalent Presentation

The **ORANGE** caps and **ORANGE** vial label borders of both vaccines are **IDENTICAL**



- Presentations are almost identical to monovalent counterparts.
- Proper organization and communication within your practice is crucial.

## PRIMARY Series

Pfizer/Moderna Ages 6m-4y  
Not Viable After (BUD/Exp.): 11/15/2022

## BOOSTER Dose

6-11 (0.25mL)  
Pfizer/Moderna Ages 12+ (0.5mL)  
Not Viable After (BUD/Exp.): 11/15/2022



# COVID-19 Vaccine Administration - Reminders

## Avoiding COVID-19 Vaccine Errors

- ✓ Develop a plan for storing the vaccines prior to administration
- ✓ Clearly label all individual syringes containing vaccines
- ✓ Prior to administration of the vaccine, ensure the following:



### Right PATIENT

- Verify patient screening information



### Right TIME

- Check FDA authorized and CDC recommended intervals for doses



### Right DOCUMENTATION

- Document vaccine administration per CDC guidance



### Right VACCINE

- Is the cap color & colored label border correct based upon the individual's age?
- Booster dose vs. primary series?
- Does the vaccine require dilution?
- Check expiration dates and Beyond-Use-Date (BUD)



### Right DOSE






- Vaccine dose is based on an individual's age
- Was the correct volume of vaccine withdrawn?



### Right ROUTE

- Authorized & approved COVID-19 vaccines are intramuscular injections. Ensure correct needle length.
- Refer to CDC resources regarding vaccine administration

# Pfizer COVID Vaccine Storage

	<p>Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)</p>  <p>Ages 12 years and older DO NOT DILUTE</p>	<p>Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY® (COVID-19 Vaccine, mRNA)</p>  <p>Ages 12 years and older DO NOT DILUTE</p>	<p>Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)</p>  <p>Ages 5 through 11 years DILUTE BEFORE USE</p>	<p>Pfizer-BioNTech COVID-19 Vaccine</p>  <p>Ages 5 through 11 years DILUTE BEFORE USE</p>	<p>Pfizer-BioNTech COVID-19 Vaccine</p>  <p>Ages 6 months through 4 years DILUTE BEFORE USE</p>
	✓	✗	✓	✓	✓
Allowed storage	ULT Freezer (-90°C to -60°C)	Freezer (-25°C to -15°C)	Refrigerator (2°C to 8°C)	Room Temperature (8°C to 25°C)	After First Puncture (2°C to 25°C)
time	12 months*	<b>DO NOT STORE</b>	10 weeks	12 hours prior to first puncture (including any thaw time)	Discard after 12 hours



# Pfizer Training

- Manufacturer holds regular trainings, updated for all current products.
- If you carry Pfizer products it is **HIGHLY RECOMMENDED** that you attend at least one of these trainings.

[www.pfizermedicalinformation.com/en-us/medical-updates](http://www.pfizermedicalinformation.com/en-us/medical-updates)

[Attendee link – Tuesday, October 18 - 3pm ET](#)

[Attendee link – Wednesday, October 19 - 12pm ET](#)

[Attendee link – Thursday, October 20 – 12pm ET](#)

[Attendee link – Tuesday, October 25 – 3 pm ET](#)

[Attendee link – Wednesday, October 26 – 12pm ET](#)

[Attendee link – Thursday, October 27 – 12pm ET](#)

# Pfizer Vaccine Resources

## Manufacturer:

- Website: [www.cvdvaccine-us.com/](http://www.cvdvaccine-us.com/)
- Live Trainings: [www.pfizermedicalinformation.com/en-us/medical-updates](http://www.pfizermedicalinformation.com/en-us/medical-updates)
- Presentation Guide: [webfiles.pfizer.com/formulation-guide](http://webfiles.pfizer.com/formulation-guide)
- Expiration Date Look-up Tool: [lotexpiry.cvdvaccine.com/](http://lotexpiry.cvdvaccine.com/)

## EUAs and FDA:

- EUAs (Fact Sheets) for providers and recipients: [www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccines](http://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccines)
- FDA Vaccine Wall Chart: [www.fda.gov/media/161752/download](http://www.fda.gov/media/161752/download)

## CDC:

- Pfizer Product Info: [www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html](http://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html)
- Pfizer Vaccine At A Glance: [www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/vaccine-at-a-glance.pdf](http://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/vaccine-at-a-glance.pdf)
- Pfizer Storage and Handling Summary: [www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/storage-summary.pdf](http://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/storage-summary.pdf)
- Pfizer Administration Summary: [www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/diluent-poster.pdf](http://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/diluent-poster.pdf)

# Pediatric Bivalent Moderna (6+)

# Moderna Bivalent Booster Ordering Opens 10/17

- Moderna bivalent booster is a single product used for anyone 6 and older
  - 0.25 mL administered to 6 through 11 years
  - 0.50 mL administered to 12+
- **Moderna bivalent product will be available to order in VIMS 8 am 10/17 through noon 10/18.**
- For Initial orders:
  - Order 100 doses of vaccine for direct shipment at frozen temperatures.
  - Direct shipments of Moderna should be placed in an approved freezer if available.
  - Do not order more than 100 doses. If you think you can use more than 100 doses in two weeks, leave a comment in VIMS with the quantity.
  - Do not order less than 100 doses initially. Routine ordering will open up in the coming weeks, at which point requests for small volumes from the Depot at refrigerated temperatures (30 day BUD) will be approved.

# Moderna Bivalent Ordering

- Unique to the Moderna bivalent product, you will need to select between two Moderna line items; pediatric (PED) or adult (ADU) intent.
- This selection determines the quantity of ancillary supplies received, not the product.
- Pediatric ancillary supplies will be twice the quantity of Adult ancillary supplies.
- Selection does not dictate administration, administer Moderna bivalent product to all eligible patients, as indicated.
- If ancillary supplies are not needed, select Adult intent and leave a comment in VIMS saying kits are not needed.

# Moderna Bivalent Presentation

**DRAFT – SUBJECT TO  
CHANGE PENDING  
REGULATORY GUIDANCE  
AND AUTHORIZATION/  
APPROVAL – SHARED  
FOR PLANNING  
PURPOSES ONLY**



## Bivalent Booster Dose Presentation

Age Group	6 years of age and older
Dose Volume	<b>Bivalent Booster Doses</b> 12 years of age and older: Each 0.5 mL 6 through 11 years of age: Each 0.25 mL
Dose Per Vial	12 years of age and older: <b>5 doses</b> 6 through 11 years of age: <b>10 doses</b>

Vial Cap Color **Dark Blue**



Vial Label **Gray Border**  
NDC 80777-282-05



Carton **Gray Border**  
NDC 80777-282-99





Dose  
Per Vial

Dose  
Volume


Vial  
Label

Carton

**Moderna COVID-19  
Vaccine  
Primary Series**  
(12 years of age and older)

Primary Series Doses only:  
**maximum of 11 doses**  
(range: 10-11 doses)

Primary Series Dose:  
**Each 0.5 mL**



**Moderna COVID-19  
Vaccine  
Primary Series\***  
(6 through 11 years of age)

Primary Series Doses:  
**5 doses**

Primary Series Dose:  
**Each 0.5 mL**



**Moderna COVID-19  
Vaccine  
Primary Series**  
(6 months through 5 years  
of age)

Primary Series Doses:  
**10 doses**


Primary Series Dose:  
**Each 0.25 mL**



**Moderna COVID-19  
Vaccine,  
Bivalent Booster Dose**  
(6 years of age and older)

Bivalent Booster Dose for  
12 years of age and older:  
**5 doses**  
  
Bivalent Booster Dose for  
6 through 11 years of age:  
**10 doses**


**Bivalent Booster Doses**  
12 years of age and older:  
**Each 0.5 mL**  
6 through 11 years of age:  
**Each 0.25 mL**



**DRAFT – SUBJECT TO  
CHANGE PENDING  
REGULATORY  
GUIDANCE AND  
AUTHORIZATION/  
APPROVAL – SHARED  
FOR PLANNING  
PURPOSES ONLY**

# Moderna Administration - Reminders

## Dose Preparation and Deployment



### Can be deployed in typical vaccine administration settings

- Inspect the vaccine prior to administration
- The vaccine may contain white or translucent product-related particulates
- If there is discoloration or other particulate matter, the vaccine should not be administered

**The Moderna COVID-19 Vaccine is administered intramuscularly**



# Moderna Vaccine Resources

## Manufacturer:

- **Website:** [eua.modernatx.com/covid19vaccine-eua/providers/](https://eua.modernatx.com/covid19vaccine-eua/providers/)
- **Moderna Office Hours:** [app.livestorm.co/moderna-na-medical/moderna-office-hours-omicron-bivalent-boosters](https://app.livestorm.co/moderna-na-medical/moderna-office-hours-omicron-bivalent-boosters)
- **Presentation Guide:** [eua.modernatx.com/covid19vaccine-eua/BivalentBoosterGuide.pdf](https://eua.modernatx.com/covid19vaccine-eua/BivalentBoosterGuide.pdf)
- **Expiration Date Look-up Tool:** <https://modernacovid19global.com/vial-lookup>

## EUAs and FDA:

- **EUAs (Fact Sheets) for providers and recipients:** [www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccines](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccines)
- **FDA Vaccine Wall Chart:** [www.fda.gov/media/161751/download](https://www.fda.gov/media/161751/download)

## CDC:

- **Moderna Product Info:** [www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html](https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html)
- **Moderna Vaccine At A Glance:** [www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/vaccine-at-a-glance.pdf](https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/vaccine-at-a-glance.pdf)
- **Moderna Storage and Handling Summary:** [www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/storage-summary.pdf](https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/storage-summary.pdf)
- **Moderna Administration Summary:** [www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/prep-and-admin-summary.pdf](https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/prep-and-admin-summary.pdf)

# Pfizer-BioNTech and Moderna Bivalent Boosters

## Bivalent Pfizer (5-11, 12+)

- Ultra Cold storage through expiration
- NO FREEZER STORAGE
- Refrigerator (2 °C to 8 °C) up to 10 weeks
- Once punctured dispose after 12 hours

### Bivalent Pfizer, 5-11

- Orange Cap, Dilution required
- 10 dose vials, min. direct order of **100 doses**
- NDC: 59267-0565-02 / CVX: 301

### Bivalent Pfizer, 12+

- Grey Cap, Do Not Dilute
- 6 dose vials, min. direct order of **300 doses**
- NDC: 59267-0304-02 / CVX: 300

## Bivalent Moderna (6+)

- NO ULTRA COLD STORAGE
- Freezer (-50°C to -15°C) through expiration
- Refrigerator (2°C to 8°C) up to 30 days
- Once punctured dispose after 12 hours
- 5 dose vials (12+), 10 dose vials (6-11)  
min. direct order of **100 doses** / 20 vials
- NDC: 80777-0282-99 / CVX: 229

## 5-11 Bivalent Booster Ordering Summary

### Pfizer bivalent booster 5-11 (orange cap)

- Offices that pre-ordered should expect vaccine deliveries early next week.
- **Routine ordering of pediatric Pfizer bivalent booster will begin on 10/24.**
  - Order in increments of 100 to receive from the distributor.
  - Orders less than 100, place a COVID only order before Thursday at 3pm for delivery the following week.
  - While demand is still high, order this product as needed for what you can use in 2-3 weeks.

### Moderna bivalent booster (6+)

- **Moderna bivalent product will be available to order in VIMS 8 am 10/17 through noon 10/18.**
  - 100 dose initial orders from the distributor. Place in freezer through expiration.
  - Will need to specify adult and pediatric intent for delivery of appropriate quantities of ancillary supplies.
- Guidance on future ordering for Moderna bivalent boosters will be communicated by email next week.

# Future of Monovalent COVID-19 Vaccine

- Deliveries may have expirations that occur before the 30 days (Moderna) and 10 week (Pfizer) BUD guidance. A BUD can not go past the expiration. **Vaccine is no longer viable after the expiration or BUD whichever occurs first.**
- We have been hearing that the monovalent products will go away in the new year.
- The assumption is that the bivalent products will become the primary series. **Please order accordingly.**

**Reminder: Place a COVID-only order for small amounts of COVID vaccine.** Small quantity orders, transferred through the depot, can not be ordered as a part of an all-vaccine order. Do not order more COVID vaccine than you need through an all-vaccine order.

# Bivalent booster for under 5

## Timeline:

- Still gathering data
- Possible availability at the end of 2022 or first quarter 2023
- Like with the under 5 primary series roll-out, providers will be the first to receive an allocation and act as the primary vaccinators for this age.

# Communication of “New” Boosters

## Communicating Bivalent Boosters with Patients

- Be thoughtful in referring to the new bivalent boosters in conversation with patients.
- The Immunization Program will continue to refer to these as “bivalent” and “monovalent” products to match the CDC and manufacturer resources we refer you to, though your patients may not be familiar with these terms.
- The Vermont Department of Health refers to the shots as “updated COVID-19 boosters”; some other outlets may be referring to this as the “new booster.”
- Ensure patients know they are eligible for these vaccines: 2 months after their primary series or last booster, regardless of past booster history.
- For a list of communication resources, see CDC’s [Resources to Promote COVID-19 Vaccines for Children & Teens](#).

# Coadministration for Flu and COVID

If your patient is in the office for one, ask about and offer the other.

[Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Providers](#) | COCA Call: reviews coadministration strategies

[Clinical Guidance for COVID-19 Vaccination | CDC](#): includes coadministration guidance

[Administering More Than Once Vaccine in the Same Day: Clinical Considerations](#) | CDC Webinar Series – 22 minute video

# Vermont Vaccine Program Updates



# AAPVT Grant Funding Now Available!

The Vermont Department of Health has opened another round of funding, that allows those practices that have applied/received funding previously or new practices to apply for a maximum grant award of \$5,000 (pending availability of funds).

Health Care Practices/Organizations may [apply online here](#) OR [apply via word here](#) and email back to Birdie Pauley at [BPauley@vtmd.org](mailto:BPauley@vtmd.org) by October 31, 2022.

Applications will be reviewed on receipt and funds will be distributed upon receipt of final project report. Reporting will be due by April 1, 2023. Reporting requirements will be distributed after the application deadline.

for more information:

[AAPVT Chapter Amended Grant Application for Flu and COVID-19 Vaccines | American Academy of Pediatrics - Vermont Chapter](#)

# 2022/2023 COVID-19 Vaccine Training

- New training will reassess provider understanding of COVID-19 vaccine ordering, administration, and management.
- Review of materials and completion of an updated attestation/assessment of understanding will be required by the primary of each practice.
- Completion required regardless of date of previous training attestation.
- Look for communication in November with links to the training webinar, resources, and new assessment.

# **New VIMS Automated E-mail reminders – Starting Nov. 1<sup>st</sup>, 2022**

## **Expired vaccine**

When a vaccine expires in your inventory, VIMS will send the primary and back-up an e-mail notification informing you. You will be asked to remove the vaccine from your unit, if still present, and submit an adjustment of waste or return in VIMS. E-mail will be repeated every 7 days until adjusted out, or your monthly reconciliation reports as administered.

## **Late Monthly Reconciliation**

A full vaccine inventory reconciliation must be done monthly, regardless of order schedule. If delayed, VIMS will send the primary and back-up an e-mail notification requesting reconciliation of inventory. An e-mail will be sent every 7 days until the inventory is reconciled.

## **Depot Request**

When part of a vaccine order will be delivered to your practice via the Depot, VIMS will send the primary and back-up an e-mail notification informing you as to which vaccines will be included in the Depot Delivery. The Vaccine Depot will send communication with details on when to expect the delivery.

# Polio vaccine

# Polio Vaccine Recommendations - Adults

## Polio vaccination in adults

Most adults were vaccinated for polio as children, and IPV is not a [routine adult vaccine](#). The CDC vaccine purchase contract does not include IPV for adults, **state-supplied IPV may not be used for adults 19+.**

However, adults [SHOULD receive a polio vaccine](#) if they are unvaccinated or incompletely vaccinated and at increased risk of exposure to poliovirus. Situations that put adults at increased risk of exposure include:

- Travelers who are going to countries where polio is epidemic or endemic
- Laboratory and healthcare workers who handle specimens that might contain polioviruses.
- Healthcare workers or other caregivers who have close contact with a person who could be infected with poliovirus.
- Unvaccinated or incompletely vaccinated adults whose children will be receiving oral poliovirus vaccine (for example, international adoptees or refugees).
- Unvaccinated or incompletely vaccinated adults living or working in a community where poliovirus is circulating.

# Polio Vaccine Recommendations - Adults

Adults who are unvaccinated or incompletely vaccinated and **at increased risk** should be given three doses of IPV at [recommended intervals](#).

You may receive requests from adults searching for the polio vaccination for any of the above reasons. **Currently, the only option is to purchase the vaccine privately or refer these patients to an administering pharmacy, or travel clinic if appropriate.** If and when the CDC contract changes to allow for IPV administration in adults, the Immunization Program will update the [Vaccine Availability Sheet](#) and communicate by e-mail.

# Polio Vaccine for Special Adult Populations

Small amount of CDC funding available to purchase polio vaccine for adult use for special populations.

This vaccine will not be in VIMS, it was privately purchased. We have a limited supply (~30 vials)

Vaccine available to DO's and PCP offices who see patients that fit the criteria.

[Global Polio - Alert - Level 2, Practice Enhanced Precautions- Travel Health Notices | Travelers' Health | CDC](#)

Working on a policy update, will get it to you as soon as it is approved.

## District Health Office – Adult Polio Vaccination Policy Update

Due to the recent polio case in New York, there has been an increased interest in polio vaccination from adults. Inactivated poliovirus vaccine (IPV) is not a part of the Centers for Disease Control and Prevention (CDC) [Adult Immunization Schedule](#). Therefore, it is not available for the Department to purchase for adults through the CDC contract. Currently, CDC does not recommend routine polio vaccination for unvaccinated adults or adults with incomplete vaccination. The state supply of IPV is not to be used for adults; it is for pediatric use only.

The Immunization Program recently received special funding that allowed the Department to private purchase poliovirus vaccine for Ukrainian adults. The Immunization Program has worked with CDC to expand the eligible population to all refugees, immigrants, and migrant workers. In identifying populations to vaccinate, refer to the [CDC website](#) on countries with circulating poliovirus.

The purpose of this limited supply is to prioritize vaccinating populations who have not had the opportunity to be vaccinated before arriving in the United States. It should not be used for travel vaccination. Since this IPV supply is available through alternative grant funding, it is available for use for all adults aged 19 years and older. This exception to the normal Vermont Adult Vaccine Program covered population (19 – 64 years), will allow increased IPV coverage for refugees, immigrants and migrant workers. |

IPV multi-dose vials can be used after puncture until their expiration date. However, vials cannot be transferred once punctured.

This vaccine will not be in VIMS. To request IPV for refugees, immigrants or migrant workers, e-mail [AHS.VDHImmunizationprogram@vermont.gov](mailto:AHS.VDHImmunizationprogram@vermont.gov) to order as needed.

If you have any questions, please e-mail [AHS.VDHImmunizationprogram@vermont.gov](mailto:AHS.VDHImmunizationprogram@vermont.gov). If you would prefer to speak by phone, please include a phone number in your e-mail.

# Polio Resources

- [Polio Vaccination: What Everyone Should Know | CDC](#)
- [What Adults in the U.S. Should Know About Polio | CDC](#)
- [Pinkbook: Poliomyelitis | CDC](#)
- [Polio Vaccination: For Healthcare Providers | CDC](#)
- [Catch-up Guidance for Children 4 months through 17 years of age-Inactivated Polio Vaccine \(IPV\) | CDC](#)
- [Vermont Vaccine Availability August 2022 | VDH](#)
- [Not Up To Date Report | VDH](#)



# **Additional COVID Information**

# Recommended COVID-19 Vaccine Trainings and Resources

## Clinical and Administration Resources

- [Summary Document for Interim Clinical Considerations](#) | CDC
- [Interim COVID-19 Immunization Schedule](#) | CDC
- [At-A-Glance COVID-19 Vaccination Schedule](#) | CDC
- [Checklist of Current Versions of COVID-19 Clinic Support Tools](#) | IAC
- [Ask the Experts about COVID-19](#) | IAC
- [Special Situations for COVID-19 Vaccination of Children and Adolescents](#) | CDC

## Webinars and Trainings


- [COVID-19 Vaccine Training Modules](#) | CDC – Offers CE credit
- [COVID-19 Vaccine Webinar Series](#) | CDC – Short videos on many topics
  - [Beyond Use Date](#) – 18 minutes
  - [Preventing Administration Errors](#) – 21 minutes
  - [Vaccinating Adolescents](#) – 24 minutes

# COVID-19 expiring vaccine

- Expiration Dates are starting to come up for certain COVID-19 vaccines
- The dates in VIMS are accurate.
- Expiration dates may also be checked online from all manufacturers
  - Pfizer - <https://lotexpiry.cvdvaccine.com/>
  - Moderna - <https://eua.modernatx.com/covid19vaccine-eua/providers/vial-lookup#vialLookupTool>
  - Janssen - <https://vaxcheck.jnj/>
  - Novavax - <https://us.novavaxcovidvaccine.com/hcp>
- Beyond Use Dates (BUD) are dependent on when a vaccine is removed from permanent storage. A BUD can not exceed an expiration date. The vaccine is not viable after expiration or BUD, whichever occurs first
  - 10 weeks after moved to refrigerator from Ultra cold for Pfizer
  - 30 days after moved to refrigerator from a standard freezer for Moderna
  - Novavax permanent storage is in the refrigerator and so BUD does not apply
  - See the [Beyond Use Date Guidance](#) for more information.

# Vaccination cards

- Vaccination cards will continue to come as a part of the ancillary supplies.
- Limited entries available on vaccination cards
- When full, start a new card and staple them together.
- Store cards securely/dispose of unused cards to prevent fraud.



**COVID-19 Vaccination Record Card**

Please keep this record card, which includes medical information about the vaccines you have received.

Last Name \_\_\_\_\_ First Name \_\_\_\_\_ MI \_\_\_\_\_  
Date of birth \_\_\_\_\_ Patient number \_\_\_\_\_

Vaccine	Product Name/Manufacturer	Lot Number	Date	Healthcare Professional or Clinic Site
1* Dose COVID-19			mm dd yy	
2* Dose COVID-19			mm dd yy	
3* Dose COVID-19			mm dd yy	
			mm dd yy	
			mm dd yy	

# **hMPXV and JYNNEOS vaccine**


# Rates of Monkeypox Cases by Vaccination Status

Unvaccinated people had:

14 times the risk of monkeypox disease compared to people who were vaccinated\*

## Rates of Monkeypox Cases by 1st Dose Vaccination Status

July 31, 2022 – September 3, 2022 (32 U.S. jurisdictions)



[Rates of Monkeypox Cases by Vaccination Status | Monkeypox | Poxvirus | CDC](#)

# JYNNEOS: Vermont Vaccine Uptake


# of doses reported in the IMR

710

◀ ● Jynneos

707

# of doses by vaccination week



Data Source: Vermont Immunization Registry (10/11/2022)

Vermont Department of Health

## Vermonters vaccinated

At least one dose

Completed

By County

Addison	12
Bennington	22
Caledonia	9
Chittenden	234
Essex	*
Franklin	17
Grand Isle	*
Lamoille	*
Orange	15
Orleans	9
Rutland	23
Washington	51
Windham	39
Windsor	31


\* Data are suppressed due to small numbers.

\*\* Data are suppressed due to secondary suppression.

**Data source:** Vermont Immunization Registry

**Data notes:** Includes doses administered since January 1, 2022.

# JYNNEOS: Vermont Vaccine Uptake



## Provider type

- Other
- Hospital
- UVMHC Infectious Disease
- Reported, not administered by that provider
- Primary care
- Office of Local Health
- Planned Parenthood



# Updated Expansion of PrEP

## Pre-Exposure Prophylaxis (PrEP)

Vaccination  
**before**  
**exposure** to  
monkeypox

- People in certain occupational exposure risk groups\*
- Gay, bisexual, and other men who have sex with men, transgender or nonbinary people who in the past 6 months have had
  - A new diagnosis of one or more nationally reportable sexually transmitted diseases (i.e., acute HIV, chancroid, chlamydia, gonorrhea, or syphilis)
  - More than one sex partner
- People who have had any of the following in the past 6 months:
  - Sex at a commercial sex venue
  - Sex in association with a large public event in a geographic area where monkeypox transmission is occurring
- Sexual partners of people with the above risks
- People who anticipate experiencing the above risks

[www.cdc.gov/poxvirus/monkeypox/interim-considerations/overview.html#anchor\\_1660077319531](https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/overview.html#anchor_1660077319531)

# JYNNEOS Vaccine: Resources

## VDH Resources

- [2022 hMPXV Outbreak Partner Toolkit | VDH](#)
- [hMPXV \(human monkeypox virus\) website | VDH](#)
- [hMPXV Fact Sheet \(healthvermont.gov\)](#)

## CDC Resources – Updated 09/28

[JYNNEOS Vaccine | CDC](#): This CDC website contains the Interim Guidance for the use of JYNNEOS vaccine including information on intervals, safety, coadministration and reporting of adverse events. CDC is updating this document regularly so check it out periodically to stay up to date with the latest guidance from CDC.

[JYNNEOS Vaccine Resources | CDC](#): includes storage and handling, standing orders, translations and administration resources. Resources added regularly.

# Questions

